Home>Topics>>Aegerion Pharmaceuticals Is Still Significantly Overvalued

Aegerion Pharmaceuticals Is Still Significantly Overvalued

Healthcare Sector and Stocks Analysis from Seeking Alpha

Tue, 19 Aug 2014

By Kanak Kanti De : Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR ) was one of the top performers in the biotechnology sector last year, gaining more than 180%. The gains were driven by investor enthusiasm for Aegerion's only approved drug, Juxtapid (lomitapide), a treatment for homozygous familial ...
Content Partners